Notable FDA HHS

FDA Requests Input on Ibogaine Clinical Trial Design for Opioid Use Disorder and PTSD

FDA seeks public comments on safety and design elements for early-phase ibogaine trials as HHS-funded studies in opioid use disorder and PTSD prepare to launch. The FDA is issuing a Request for Information (RFI) to gather public input on the design and safety considerations for early-phase...

The deep analysis — cross-item commentary and how this topic has evolved — is part of SignalHealth Pro.

Start a 14-day Pro trial — $9/month

Sources — verify every claim

Health and Human Services Department, Food and Drug Administration · Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information · Oct 6

Trust record

Agent curated